Insmed (IM8N) Stock Forecast & Price Target

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IM8N Analyst Ratings

Strong Buy

20 Buy

0 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IM8N Stock 12 Month Forecast

Average Price Target

€176.66

▲(63.97% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is €176.66 with a high forecast of €216.58 and a low forecast of €150.63. The average price target represents a 63.97% change from the last price of €107.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"€88","217":"€217","120.25":"€120.3","152.5":"€152.5","184.75":"€184.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":216.58352346,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€216.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":176.6631036063158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€176.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150.62804718,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€150.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,120.25,152.5,184.75,217],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.78,106.91873257384616,116.05746514769231,125.19619772153845,134.33493029538462,143.47366286923076,152.61239544307693,161.75112801692308,170.88986059076922,180.0285931646154,189.16732573846156,198.3060583123077,207.44479088615384,{"y":216.58352346,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.78,103.84793104663967,109.91586209327936,115.98379313991903,122.0517241865587,128.1196552331984,134.18758627983806,140.25551732647773,146.3234483731174,152.39137941975707,158.45931046639674,164.52724151303642,170.59517255967612,{"y":176.6631036063158,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.78,101.84523439846154,105.91046879692308,109.97570319538463,114.04093759384617,118.10617199230771,122.17140639076923,126.23664078923078,130.3018751876923,134.36710958615384,138.4323439846154,142.49757838307693,146.56281278153847,{"y":150.62804718,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":122,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.59,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.02,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.78,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€216.58

Average Price Target€176.66

Lowest Price Target€150.63

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

€173.8

Buy

61.32%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Conor MacKay

BMO Capital

€171.13

Buy

58.83%

Upside

Reiterated

10/05/26

BMO Capital Sticks to Its Buy Rating for Insmed (INSM)

Maxwell Skor

Morgan Stanley

€194.3

Buy

80.34%

Upside

Reiterated

10/02/26

Insmed: Overweight Rating Reaffirmed as Brinsupri Momentum Drives Raised 2026 Guidance; Price Target Maintained at $218

Eliana Merle

Barclays

€211.24→€184.5

Buy

71.24%

Upside

Reiterated

09/30/26

Barclays Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

€155.98

Buy

44.77%

Upside

Reiterated

09/28/26

Wall Street Analysts Are Bullish on Top NA Picks

Andrea Newkirk

Goldman Sachs

€167.56

Buy

55.52%

Upside

Initiated

09/24/26

Wall Street Analysts Are Bullish on Top NA Picks

Jason Zemansky

Bank of America Securities

€190.74

Buy

77.03%

Upside

Reiterated

09/21/26

Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214

Adam Walsh

Roth MKM

€188.95→€176.48

Buy

63.80%

Upside

Reiterated

09/15/26

Roth MKM Remains a Buy on Insmed (INSM)

Leonid Timashev

RBC Capital

€173.8

Buy

61.32%

Upside

Reiterated

08/25/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Andrew Fein

H.C. Wainwright

€196.08

Buy

82.00%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)

Danielle Brill

Truist Financial

€164.89→€173.8

Buy

61.32%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Gavin Clark-Gartner

Evercore ISI

€142.61→€151.52

Buy

40.63%

Upside

Reiterated

08/07/26

Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI

Ashwani Verma

UBS

€147.95→€153.3

Buy

42.29%

Upside

Reiterated

08/07/26

Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS

Ritu Baral

TD Cowen

€216.58

Buy

101.02%

Upside

Reiterated

08/06/26

Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating

Faisal Khurshid

Jefferies

€142.61→€155.98

Buy

44.77%

Upside

Reiterated

08/06/26

Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

€173.8

Buy

61.32%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Conor MacKay

BMO Capital

€171.13

Buy

58.83%

Upside

Reiterated

10/05/26

BMO Capital Sticks to Its Buy Rating for Insmed (INSM)

Maxwell Skor

Morgan Stanley

€194.3

Buy

80.34%

Upside

Reiterated

10/02/26

Insmed: Overweight Rating Reaffirmed as Brinsupri Momentum Drives Raised 2026 Guidance; Price Target Maintained at $218

Eliana Merle

Barclays

€211.24→€184.5

Buy

71.24%

Upside

Reiterated

09/30/26

Barclays Remains a Buy on Insmed (INSM)

Jessica Fye

J.P. Morgan

€155.98

Buy

44.77%

Upside

Reiterated

09/28/26

Wall Street Analysts Are Bullish on Top NA Picks

Andrea Newkirk

Goldman Sachs

€167.56

Buy

55.52%

Upside

Initiated

09/24/26

Wall Street Analysts Are Bullish on Top NA Picks

Jason Zemansky

Bank of America Securities

€190.74

Buy

77.03%

Upside

Reiterated

09/21/26

Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214

Adam Walsh

Roth MKM

€188.95→€176.48

Buy

63.80%

Upside

Reiterated

09/15/26

Roth MKM Remains a Buy on Insmed (INSM)

Leonid Timashev

RBC Capital

€173.8

Buy

61.32%

Upside

Reiterated

08/25/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Andrew Fein

H.C. Wainwright

€196.08

Buy

82.00%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)

Danielle Brill

Truist Financial

€164.89→€173.8

Buy

61.32%

Upside

Reiterated

08/10/26

Truist Financial Remains a Buy on Insmed (INSM)

Gavin Clark-Gartner

Evercore ISI

€142.61→€151.52

Buy

40.63%

Upside

Reiterated

08/07/26

Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI

Ashwani Verma

UBS

€147.95→€153.3

Buy

42.29%

Upside

Reiterated

08/07/26

Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS

Ritu Baral

TD Cowen

€216.58

Buy

101.02%

Upside

Reiterated

08/06/26

Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating

Faisal Khurshid

Jefferies

€142.61→€155.98

Buy

44.77%

Upside

Reiterated

08/06/26

Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PLSEPulse Biosciences

SLDBSolid Biosciences

MDWDMediwound

TRVITrevi Therapeutics

WSTWest Pharmaceutical Services

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months

Tiago FauthRaymond James

Success Rate

12/17 ratings generated profit

Average Return

+43.32%

Copying Tiago Fauth's trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +43.32% per trade.

1 Year

Tiago FauthRaymond James

Success Rate

15/17 ratings generated profit

Average Return

+82.68%

Copying Tiago Fauth's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +82.68% per trade.

2 Years

Tiago FauthRaymond James

Success Rate

14/17 ratings generated profit

Average Return

+179.35%

Copying Tiago Fauth's trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +179.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IM8N Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IM8N has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IM8N average Analyst price target in the past 3 months is 176.66.

Each month's total comprises the sum of three months' worth of ratings.

IM8N Financial Forecast

IM8N Earnings Forecast

Next quarter’s earnings estimate for IM8N is -€0.35 with a range of -€0.80 to -€0.08. The previous quarter’s EPS was -€0.05. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Sales Forecast

Next quarter’s sales forecast for IM8N is €444.46M with a range of €406.61M to €466.30M. The previous quarter’s sales results were €378.57M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Stock Forecast FAQ

What is DE:IM8N’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 176.66.

What is DE:IM8N’s upside potential, based on the analysts’ average price target?

Insmed has 63.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Insmed a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy, which is based on 20 buy ratings, 0 hold ratings and 0 sell ratings.

What is Insmed’s share price target?

The average share price target for Insmed is 176.66. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €216.58 ,and the lowest forecast is €150.63. The average share price target represents 63.97% Increase from the current price of €107.74.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Insmed?

To buy shares of DE:IM8N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Insmed (IM8N) Stock Forecast & Price Target

IM8N Analyst Ratings

IM8N Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

IM8N Analyst Recommendation Trends

IM8N Financial Forecast

IM8N Earnings Forecast

IM8N Sales Forecast

IM8N Stock Forecast FAQ

Detailed List of Analyst Forecasts